

Express Mail No. EL 477 032 133 USSheet 1 of 1

SUPPLEMENTAL LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO.	APPLICATION NO.
		9457-023	09/873,234
		APPLICANT	
		Palazzini and Gambaro	
		FILING DATE	GROUP
		June 4, 2001	TBA
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
PL	BR	Shin, J. of the Med. Soc. of Toho Univ, vol. 38, no. 3, pp. 374-382 (1991).	
PL	BS	Mogami, J. of the Jap. Diabetes Soc., (Abstract, p. 111) vol. 34, no. 2, pp. 105-111 (1991).	
PL	BT	Shin et al., Current Status of Prev. and Treat. of Diabetic complications, pp. 567-569 (1990).	
PL	BU	Kaizu et al., J. of Diabetic Complications, vol. 5, nos. 2-3, pp. 92-94 (1991).	
EXAMINER		DATE CONSIDERED	
<i>[Signature]</i>		12-13-02	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

RECEIVED
JUN 12 2002
TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

9457-023

APPLICATION NO.

09/873,234

APPLICANT

Palazzini and Gambaro

FILING DATE

June 4, 2001

GROUP

1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PL	BV	3,536,809	10/27/70	Applezweig et al.			
↑	BW	3,598,123	8/10/71	Zaffaroni et al.			
	BX	3,845,770	11/5/74	Theeuwes et al.			
	BY	3,916,899	11/4/75	Theeuwes et al.			
	BZ	4,008,719	2/22/77	Theeuwes et al.			
	CA	4,945,086	7/31/90	Benitz et al.			
	CB	5,010,063	4/23/91	Piani et al.			
	CC	5,059,595	10/22/91	Le Grazie			
	CD	5,073,643	12/17/91	Marshall et al.			
	CE	5,104,860	4/14/92	Piani et al.			
	CF	5,120,548	6/9/92	McClelland et al.			
	CG	5,354,556	10/11/94	Sparks et al.			
	CH	5,380,716	1/10/95	Conrad et al.			
	CI	5,405,949	4/11/95	Ungarelli et al.			
	CJ	5,410,039	4/25/96	Ungarelli et al.			
	CK	5,430,132	7/4/95	Silvano et al.			
	CL	5,430,133	7/4/95	Piani et al.			
	CM	5,464,942	11/7/95	Sakurai et al.			
	CN	5,470,965	11/28/95	Baldacci et al.			
	CO	5,543,403	8/6/96	Petitou et al.			
	CP	5,585,361	12/17/96	Burns et al.			
	CQ	5,591,767	1/7/97	Mohr et al.			
	CR	5,639,476	6/17/97	Oshlack et al.			
	CS	5,672,334	9/30/97	Ranney			
↓	CT	5,674,633	10/7/97	Santus et al.			
PL	CU	5,733,566	3/31/98	Lewis			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PL	CV	EP 0 710 483	5/8/96	Europe				
PL	CW	EP 0 624 374	11/17/94	Europe				
PL	CX	EP 0 950 413	10/20/99	Europe				

PL	CY	EP 0 497 162	8/5/92	Europe					
↓	CZ	EP 1 016 410	7/5/00	Europe					
↓	DA	EP 0 485 748 A2	5/20/92	Europe					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PL	DB	Gaddi et al., 1996, "Meta Analysisi of Some Results of Clinical Trials on Sulodexide Therapy in Peripheral Occlusive Arterial Disease", J. of Int. Med. Res. 24:389-406
↓	DC	International Search Report, PCT International Application No. PCT/US01/18411, filed June 6, 2001.
↓	DD	Nielsen et al., 1999, "Transcapillary escape rate and albuminuria in Type II diabetes. Effect of short term treatment with low molecular weight heparin", Diabetologia 42:60-67
↓	DE	Solini et al., 1997, "Glycosaminoglycans Delay the Progression of Nephropathy in NIDDM", Diabetes Care 20:819-823
↓	DF	Sorrenti et al., 1997, "Glycosaminoglycans as a Possible Tool for Micro and Macroalbuminuria in Diabetic Patients", J. of Int. Med. Res. 25:81-86

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED
SEP 26 2002
TECH CENTER 1600/2900